8-K: Voyager Therapeutics Announces CFO Transition and Appointment of New Principal Financial Officer

Voyager Therapeutics' Chief Financial Officer, Peter P. Pfreundschuh, is stepping down, with Robin Swartz appointed as the new principal financial officer, effective April 12, 2024.

Summary

• Voyager Therapeutics has announced the departure of its Chief Financial Officer, Peter P. Pfreundschuh, effective April 12, 2024.
• Mr. Pfreundschuh will transition to a Senior Financial Advisor role until May 5, 2024, to assist with the handover of his responsibilities.
• He will receive a severance package including 12 months of salary continuation, a prorated 2024 bonus, and continued health insurance coverage for up to 12 months.
• The company has also agreed to a consulting agreement with Mr. Pfreundschuh, effective May 5, 2024, to assist with the transition of his responsibilities.
• Robin Swartz, the current Chief Operating Officer, has been appointed as the new principal financial officer and principal accounting officer, effective April 12, 2024.
• Ms. Swartz has held various senior positions at Voyager Therapeutics since January 2021 and has extensive experience at Genzyme Corporation and Sanofi Genzyme.

Sentiment

Score: 7

Explanation: The document outlines a planned executive transition with clear terms and a smooth handover process. While the departure of a CFO can be a concern, the appointment of an internal candidate and the consulting agreement suggest a well-managed transition. The sentiment is therefore moderately positive.

Positives

• The transition plan includes a consulting agreement to ensure a smooth handover of responsibilities.
• Mr. Pfreundschuh will continue to assist the company during the transition period.
• The company has appointed an experienced internal candidate, Robin Swartz, as the new principal financial officer.
• The severance package provides financial security for Mr. Pfreundschuh during his transition.

Negatives

• The departure of the CFO could create some uncertainty in the short term.
• The company will incur costs associated with the severance package and consulting agreement.

Risks

• There is a risk of disruption during the transition period.
• The company needs to ensure a smooth handover of financial responsibilities to the new principal financial officer.
• The company needs to ensure compliance with all legal and regulatory requirements during the transition.

Future Outlook

The company expects to file a copy of the Consulting Agreement as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.

Management Comments

• The company and Mr. Pfreundschuh have mutually agreed to establish terms for his separation from employment.
• The company has agreed to provide severance benefits to Mr. Pfreundschuh in accordance with the terms of the Separation Agreement.
• The company has appointed Robin Swartz as the new principal financial officer and principal accounting officer.

Industry Context

Executive transitions are common in the biotech industry, and this announcement reflects a planned change in leadership at Voyager Therapeutics. The appointment of an internal candidate suggests a focus on continuity and stability.

Comparison to Industry Standards

• Executive transitions are a normal part of corporate life, and the terms of the separation agreement appear to be within industry norms.
• Severance packages typically include salary continuation, bonus payments, and health insurance coverage, which are all included in Mr. Pfreundschuh's package.
• The appointment of an internal candidate to a key financial role is a common practice in the biotech industry, as it provides continuity and reduces the risk of disruption.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CFO transition.
• Employees may be affected by the change in leadership.
• The company's financial reporting and compliance processes will be impacted by the transition.

Next Steps

• The company will file the Consulting Agreement as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
• Robin Swartz will assume her new role as principal financial officer and principal accounting officer on April 12, 2024.
• Peter P. Pfreundschuh will transition to his role as Senior Financial Advisor until May 5, 2024.
• The company will enter into a consulting agreement with Mr. Pfreundschuh on May 5, 2024.

Key Dates

Keywords

CFO, Chief Financial Officer, financial officer, executive transition, severance, consulting agreement, Robin Swartz, Peter P. Pfreundschuh, management change, corporate governance